Georg-Speyer-Haus

What Georg-Speyer-Haus does

Georg-Speyer-Haus (legally Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus) is a private non-profit research foundation founded in 1904 in Frankfurt am Main, Germany, originally established in honor of Nobel laureate Paul Ehrlich. The institute conducts basic and translational cancer research with a thematic focus on the tumor microenvironment, tumor-stroma crosstalk, and innate immunity in cancer, employing approximately 100 staff with an annual financial volume of approximately €12 million. Its director, Prof. Dr. Florian Greten, has held the position since August 2013 and is recognized as a Clarivate Highly Cited Researcher (2023) and ERC Advanced Grant holder.

The institute operates several research platforms: the DKTK Organoid Platform, the FCI Organoid Biobank, a microbiome-cancer interaction platform, and patient-derived biomaterial and biomarker development pipelines. It is structurally integrated into Frankfurt's cancer research ecosystem through the Frankfurt Cancer Institute (FCI/LOEWE), the DKTK consortium, the DFG-funded Collaborative Research Center TRR 417, and partnership with the Goethe University Frankfurt University Hospital. Wissenschaftsrat certification confirms its standing as a publicly recognized non-university research institution.

Georg-Speyer-Haus operates a non-commercial funding model. Equal institutional baseline funding is provided by the Federal Ministry of Health (BMG) and the Hessian Ministry of Higher Education, Research and the Arts (HMWK), supplemented by competitive grants from the DFG, the European Research Council (ERC), Deutsche Krebshilfe, and similar bodies, plus private donations. The institute does not sell products or services; its outputs are peer-reviewed publications, trained researchers, translational findings, and research infrastructure that feed downstream into academic and clinical channels.

Name

Georg-Speyer-Haus

Legal name

Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus

Website

https://georg-speyer-haus.de

Company type

Private

Founded year

1904

Operating status

Operating

Headcount range

51–100 employees

Short description

Georg-Speyer-Haus is a private non-profit cancer research foundation in Frankfurt am Main, Germany, conducting basic and translational research on the tumor microenvironment with approximately 100 employees and an annual operating budget of around €12 million.

Ownership category

akta.pro rank

Product category

Cancer Research and Translational Oncology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• Tumor microenvironment research
• Cancer immunotherapy research
• Translational oncology research
• Patient-derived organoid models
• Microbiome cancer research

Headquarters

HQ city

Frankfurt

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Institutional funding (BMG and HMWK): Equal institutional funding from the Federal Ministry of Health (BMG) and the Hessian Ministry of Science and the Arts (HMWK), providing the base operational budget for the foundation.
2. Third-party project funding: Scientists obtain competitive third-party funding from public research funders (DFG, BMBF, ERC, Deutsche Krebshilfe) and private foundations (Else Kröner-Fresenius-Stiftung, Beug Stiftung, Dr. Rolf M. Schwiete Stiftung, etc.) for specific research projects.
3. Donations and sponsorship: Income from donations by private individuals and organizations, including support from the Freunde und Förderer des Georg-Speyer-Hauses e.V. society of friends and sponsors. The institute receives donations via online platforms and bank transfers.
4. Industry cooperation agreements: Income from cooperation agreements with companies including Affimed GmbH, Amazentis SA, Sana Biotechnology Inc., Vandria SA, and CANDRIAM Institute for Sustainable Development, as well as income from the foundation's capital.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Georg-Speyer-Haus is a non-profit private research foundation that conducts basic and translational cancer research focused on the tumor microenvironment, with the goal of identifying new therapeutic approaches for cancer. Core scientific programs investigate immunotherapy resistance in colorectal cancer (notably microsatellite-stable CRC), microbiome–cancer–circadian rhythm interactions, immune aging (urolithin A), and tumor biology using patient-derived organoid and in vivo models, supported by a structured Graduate School, the Frankfurt Cancer Conference, and a public museum laboratory outreach program.

Product overview

Georg-Speyer-Haus is a private biomedical research foundation (Institute for Tumor Biology and Experimental Therapy) established in 1904, focused on cancer research. The institute does not offer commercial products or services; instead, it conducts fundamental research on the tumor microenvironment, publishes scientific findings, operates a Graduate School for research training, hosts the annual Frankfurt Cancer Conference, and provides public tours and educational programs. Its work includes ERC-funded research projects (INFLAME-TME, PLASTICAN), microbiome research, and various research groups studying tumor biology, immunotherapy, and cancer metabolism.

Differentiator

Problem solved

Functional benefit

Products and services

• Basic and translational tumor microenvironment research
• Graduate School and doctoral research training
• Frankfurt Cancer Conference
• DKTK Organoid Platform and FCI Organoid Biobank
• Industry cooperation and licensing partnerships
• Museum laboratory and public guided tours

Quantifiable outcome

• ERC Proof of Concept Grant 2026 (up to €150,000) awarded for INFLAME-TME project targeting immunotherapy-resistant colorectal cancer
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Transregional Collaborative Research Center TRR 417coreStrategic or Co-development Partner · 1 January 2025DFG-funded TRR 417 ('The Sinister Network of Colorectal Tumors') is led by Goethe University Frankfurt and involves collaboration with the Universities of Erlangen-Nuremberg and Freiburg, Georg-Speyer-Haus, and the Paul-Ehrlich-Institut. The research focuses on the tumor microenvironment in colorectal cancer, with GSH scientists leading key subprojects.
• Frankfurt Cancer Institute (FCI / LOEWE-Zentrum Frankfurt Cancer Institute)coreStrategic or Co-development Partner · 13 December 2023The Frankfurt Cancer Institute (FCI) is a LOEWE Excellence Center co-located with Georg-Speyer-Haus. Georg-Speyer-Haus Director Prof. Dr. Florian Greten serves as speaker of the FCI. The partnership includes joint research groups, shared PhD student funding, a clinician scientist program (MSNZ), an organoid biobank, joint events (FCI Lectures), and co-organization of the Frankfurt Cancer Conference. The FCI provides fully-funded PhD positions to GSH researchers.
• Goethe University Frankfurt am MaincoreStrategic or Co-development PartnerGeorg-Speyer-Haus is associated with Goethe University Frankfurt through a cooperation agreement. The partnership includes joint research groups, shared doctoral researchers, Heisenberg Professorship appointments, clinical translation through university hospitals, and joint educational programs. Many GSH researchers hold dual affiliations.
• Deutsches Konsortium für Translationale Krebsforschung (DKTK)coreStrategic or Co-development PartnerGeorg-Speyer-Haus participates in the DKTK, a German Cancer Consortium focused on translational cancer research. The institute hosts the DKTK Organoid Platform and contributes to DKTK research programs including work on colorectal cancer and bone metastasis.
• Paul-Ehrlich-InstitutcoreStrategic or Co-development PartnerThe Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedical Drugs) collaborates with Georg-Speyer-Haus within TRR 417 and as co-organizer of the Frankfurt Cancer Conference. Both institutes share historical roots from their original co-location in Frankfurt.
• Klinikum der Johann Wolfgang-Goethe UniversitätminorStrategic or Co-development PartnerCooperation with Goethe University Hospital for clinical translation of research findings, including joint clinician scientist positions and patient-derived biomaterial research.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• European Institute of Oncology (IEO): Milan-based cancer research and treatment institute founded by Umberto Veronesi. Comparable in combining foundation governance with translational cancer research and clinical programs, especially in gastrointestinal and immunotherapy research.
• Netherlands Cancer Institute (NKI): Dutch specialist cancer research and treatment center combining fundamental and clinical oncology. Directly comparable in scope (tumor biology, immunotherapy, translational pipeline) and as a publicly co-funded specialist cancer institute.
• Max Delbrück Center for Molecular Medicine (MDC): Berlin-based Helmholtz research center focused on molecular medicine, including cancer. Comparable as a German biomedical research institute with a strong Berlin/Brandenburg academic partner network and a similar blend of basic and translational research.
• Institut Curie: French non-profit foundation combining a cancer research center with a hospital. Comparable to Georg-Speyer-Haus in combining long-standing heritage, foundation governance, and a translational cancer research mandate including tumor biology and immunotherapy.
• Institute of Cancer Research (ICR): UK-based research institute and university college focused exclusively on cancer. Highly comparable to Georg-Speyer-Haus in mission (basic + translational cancer research), funding mix (charity/grant-led), and international collaboration patterns.
• Francis Crick Institute: London-based biomedical discovery institute with a major cancer research portfolio. Comparable as a UK/European flagship research institute with foundation/charitable status, public funding base, and translational ambition across tumor biology.
• IRB Barcelona: Catalan research institute with programs in oncology, cell biology, and computational biology. Comparable as a European mid-sized research institute focused on fundamental cancer biology and translational collaborations.
• Beatson Institute for Cancer Research: Scottish cancer research institute affiliated with the University of Glasgow focused on tumor microenvironment, cell signaling, and metastasis. Closely comparable to Georg-Speyer-Haus in scientific niche (TME-focused translational cancer research) and institute scale.

Broad incumbents

• Memorial Sloan Kettering Cancer Center: US-based comprehensive cancer center combining research and clinical care. Comparable thematically as a leading translational cancer research institution, but operates at materially larger scale and with different (US/charity) funding dynamics than Georg-Speyer-Haus.
• German Cancer Research Center (DKFZ): Germany's largest national cancer research center, also publicly funded and focused on basic and translational oncology. Comparable because it addresses the same scientific mission (tumor biology, immunotherapy) under a similar German institutional funding model, but operates at a much larger scale than Georg-Speyer-Haus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/chemotherapeutisches-forschungszentrum-georg-speyer-haus-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Georg-Speyer-Haus